Navigation Links
Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
Date:12/21/2010

HOUSTON, Dec. 21, 2010 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced $3 million in Convertible Note funding. The new funds will be used to prepare for Phase II trials of BPX-101, the company's DeCIDe™ vaccine for metastatic castrate resistant prostate cancer (mCRPC), and CaspaCIDe™, a cell therapy safety switch under initial development in the hematopoietic stem cell therapy (HSCT) setting.

The new funding brings the total raised to date to $11.5 million, including $1.45 million from the Texas Emerging Technology Fund, $9.8 million from angel investors, and additional seed capital from founders. Of the new funds, $1.5 million was from current investors, and $1.5 million from new investors. A Series B financing is expected to close in the first half of 2011, with funds to be used to support the company's Phase II clinical trial programs. The Notes are intended to convert automatically into Series B Preferred stock at that time.

The company will report results of a Phase I/II trial of BPX-101 in patients with mCRPC on February 17, 2011, at the ASCO/ASTRO/SUO 2011 Genitourinary Cancers Symposium in Orlando, FL. Interim results of the Phase I "CASPALLO" trial of a CaspaCIDe™ donor lymphocyte infusion following haploidentical HSCT, conducted by Dr. Malcolm Brenner and colleagues at the Center for Cell and Gene Therapy at Baylor College of Medicine, were reported earlier this month at the 52nd American Society of Hematology Annual Meeting. Administration of CaspaCIDe™ T cells resulted in successful immune system reconstitution, while administration of the suicide gene activating agent AP1903 upon emergence of Graft versus Host Disease (GvHD) rapidly ablated residual allo-reactive T cells and abrogated early GvHD, whilst preserving anti-viral specificity.

"Our investors recognize that the unprecedented clinical results seen with our two lead clinical products provide a high level of validation for our underly
'/>"/>

SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive ... helped cut the rate of infection with a dangerous ... percent. Clostridium difficile, or C.diff, is a ... life-threatening inflammation of the colon. A recent article in ... Clostridium difficile Infection in the United States ...
(Date:2/27/2015)... Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" ... today announced financial results for its first quarter ended ... months ended December 31, 2014, revenue was $1,336,685. Operating ... $229,820 or $0.02 per share.  Covalon,s ... am very pleased with the significant progress we have ...
(Date:2/27/2015)... 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... it acquired Bionik Laboratories, Inc., a Toronto ... to qualified accredited investors of units consisting of its ... approximately $6.2 million. Shares of the Company,s common stock ... under the symbol "DWTPD" until FINRA,s approval of the ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... West Pharmaceutical Services, Inc. (NYSE: WST ) today ...  Summary comparative results were as follows: ($ millions, except per-share ... $ 281.8Gross Profit , 84.6 , 83.2Reported Operating Profit , ... 30.5 , 30.9Reported Diluted EPS , $ 0.57 , $ ...
... SEATTLE, July 28, 2011 Cell Therapeutics, Inc. ("CTI" or ... its efforts to develop its late stage oncology pipeline to ... ended June 30, 2011. "In the second quarter, ... the FDA,s Office of New Drugs ("OND") in allowing us ...
Cached Medicine Technology:West Announces Second Quarter 2011 Results 2West Announces Second Quarter 2011 Results 3West Announces Second Quarter 2011 Results 4West Announces Second Quarter 2011 Results 5West Announces Second Quarter 2011 Results 6West Announces Second Quarter 2011 Results 7West Announces Second Quarter 2011 Results 8West Announces Second Quarter 2011 Results 9West Announces Second Quarter 2011 Results 10West Announces Second Quarter 2011 Results 11West Announces Second Quarter 2011 Results 12West Announces Second Quarter 2011 Results 13West Announces Second Quarter 2011 Results 14West Announces Second Quarter 2011 Results 15West Announces Second Quarter 2011 Results 16Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 2Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 3Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 4Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 5Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 6
(Date:2/28/2015)... 28, 2015 A case management conference ... that have been filed by law firms including Bernstein ... in March, the Firm notes. , According to ... in the federal litigation will meet on March 13, ... prescription therapy treatments designed to raise levels of the ...
(Date:2/28/2015)... Ohio (PRWEB) February 28, 2015 ... Motivational? Supportive? Strategic? , There are all kinds ... strengths. To raise awareness of the advantages and ... firm PeopleKeys is launching a new product this ... clients better understand the connection between personality type, ...
(Date:2/28/2015)... The noted Friedman Dental Group of South ... relaunched their website. The new version of the site ... new section about their team members. Potential and current ... of each Friedman Dental Group team member including new ... to provide our patients with the opportunity to get ...
(Date:2/28/2015)... 28, 2015 Developers of FCPX ... new overlay plugin for Final Cut Pro X entitled FCPX ... Overlay Chromatic gives users total control over 6k lens dirt ... of Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed ... use interface.” , FCPX Overlay Chromatic Grunge 6K is a ...
(Date:2/28/2015)... “ Powermod ” was featured on NewsWatch as ... at the latest and coolest technology products and services available ... a technology expert, conducted the review and shared with viewers ... Getting stuck with a low battery and no way to ... face on a daily basis. Even when a person does ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2
... A major research company with expertise in managing clinical ... Medical Campus to more efficiently bring the latest stem ... formally known as the Colorado Prevention Center, officially moved ... from the campus on Friday., It is the ...
... poor judges of their patients, health beliefs, according to ... A&M University and Paul Haidet from The Pennsylvania State ... is better the more patients are involved by asking ... for care. Their analysis 1 of how ...
... undergo cardiopulmonary bypass (CPB) during surgery for less ... suffer any impairments in neurocognitive abilities, such as ... Researchers from The Children,s Hospital of Philadelphia, in ... Pediatrics , reported on neuropsychological effects after surgery ...
... , , , , ... AUDIO: Scientists at Washington University School of Medicine in St. ... Click here for more information. , , ... , , , , , , ...
... Gardner HealthDay Reporter , THURSDAY, July 22 (HealthDay ... favorite pastimes -- sitting around -- the shorter their average ... remained even after researchers factored out obesity or the level ... a study of more than 120,000 American adults. It,s ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, July ... face a greater risk of having a stillborn child if ... treatments, a new study finds. Although neither boys nor ... that might affect their offspring, radiation damage to the uterus ...
Cached Medicine News:Health News:University of Colorado joins with major research firm to partner on stem cell research 2Health News:Doctors don't 'get' their patients 2Health News:Heart bypass for uncomplicated heart surgery does not reduce neurocognitive function in children 2Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 2Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 3Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 4Health News:The Longer You Sit, the Shorter Your Life Span: Study 2Health News:Radiation for Childhood Cancer Can Boost Risk of Stillbirth Later 2Health News:Radiation for Childhood Cancer Can Boost Risk of Stillbirth Later 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: